DEXCOM CLASS ACTION LAWSUIT: THE OPTIMUM INVESTOR GUIDE

dexcom SUBMISSION FORM

click here to call us

free case evaluation

INTRODUCTION TO THE DEXCOM CLASS ACTION LAWSUIT

Call Timothy L. Miles today for a free case evaluation in the DexCom class action lawsuit

The DexCom class action lawsuit seeks to represent purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) publicly traded securities between January 8, 2024 and July 25, 2024, inclusive (the “Class Period”). Captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.), the DexCom class action lawsuit charges DexCom and certain of DexCom’s top executives with violations of the Securities Exchange Act of 1934.

If you have suffered losses in DexCom stock and are interested in becoming the lead plaintiff in the DexCom class action lawsuit or have any inquiries regarding your rights as a shareholder, please reach out to DexCom Stock Loss Lawyer Timothy L. Miles at no cost.  You can contact him by calling 855/846-6529, sending an e-mail to [email protected], or filling out a contact form. 

Lead plaintiff motions for the DexCom class action lawsuit must be filed with the court no later than October 21, 2024.

---

allegations in the DexCom class action lawsuit

DexCom is a medical device company that focuses on the design, development, and commercialization of continuous glucose monitoring systems. The allegations in the DexCom class action lawsuit can be summarized as follows:
    1. False Statements Concerning Growth, Earnings Potential and Margins

• According to the lawsuit, throughout the Class Period made false and/or misleading statements and/or failed to disclose that DexCom’s optimistic reports of growth, earnings potential, and anticipated margins fell far short of reality as DexCom relied far too heavily on its ability to attract new customers while keeping existing distribution channels afloat.​​

    2. Reduced Revenue Guidance for FY 2024

• On July 25, 2024, DexCom announced its financial results for the second quarter of fiscal year 2024 and reduced its revenue guidance for the full fiscal year 2024, attributing its results and lowered guidance on their execution of “several key strategic initiatives” which “did not meet [their] high standards.” 

      ​3. Stock Collapses

• On this news, the price of DexCom stock fell nearly 41%, according to the DexCom class action lawsuit, immediately erasing nearly half the company's market capitalization. 

THE LEAD PLAINTIFF DEADLINE IN THE DexCom class action lawsuit

​Lead plaintiff motions for the DexCom ​class action lawsuit must be filed with the court no later than October 21, 2024.​
When a securities class action is filed such as the DexCom class action lawsuit:

1. The person who files the first complaint is required to publish a notice announcing the filing.
2. Anyone who wants to be lead plaintiff on behalf of the class must thereafter file a motion to be appointed as lead plaintiff(s) no later than 60 days after the notice was published. 

YOU HAVE TWO CHOICES IF YOU RECEIVE A NOTICE IN THE DEXCOM CLASS ACTION LAWSUIT

​​First, read the notice very carefully.  You have two choices. 

• First, you can do nothing and remain a member of the class represented by lead counsel. 
• Second, if you believe you have a large enough loss to justify it, you can opt out of the DexCom class action lawsuit and file your own separate lawsuit.

​Note, that if you opt-out, you will not be able to participate in any settlement or recovery obtained in the DexCom class action lawsuit. 

THE LEAD PLAINTIFF PROCESS IN THE DexCom CLASS ACTION LAWSUIT

Call us today for a free case evaluation in the DexCom class action lawsuit

The Private Securities Litigation Reform Act of 1995 (PSLRA) permits any investor who purchased and suffered losses in DexCom​​ stock to seek appointment as lead plaintiff in the DexCom class action lawsuit.

• A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. 
• A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit.
• The lead plaintiff can select a law firm of its choice to litigate the securities class action lawsuit. 
• An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. 

---

THE BENEFITS OF SERVING AS A LEAD PLAINTIFF

1. Negotiating more competitive attorney fees and reducing litigation costs.
2. Managing the litigation by overseeing the progress of the case and reviewing important filings.
3. Participating in mediation and settlement discussions.
4. Having a voice in decision-making processes regarding the settlement.
5. No financial risk, as lead counsel covers all costs and expenses and are paid only if they secure a  settlement or judgment recovery for the class
6. Potentially enjoying long-term benefits from governance reform resulting from the litigation.

THE RESPONSIBILITIES THE LEAD PLAINTIFF WILL HAVE

1. Negotiating more competitive attorney fees and reducing litigation costs.
2. Managing the litigation by overseeing the progress of the case and reviewing important filings.
3. Participating in mediation and settlement discussions.
4. Having a voice in decision-making processes regarding the settlement.
5. No financial risk, as lead counsel covers all costs and expenses and are paid only if they secure a  settlement or judgment recovery for the class
6. Potentially enjoying long-term benefits from governance reform resulting from the litigation.

ELIGIBILITY CRITERIA FOR LEAD PLAINTIFF APPOINTMENT

To be eligible for appointment as the lead plaintiff in the DexCom class action lawsuit, an investor must meet the following criteria:

1. Securities Acquisition: The investor must have purchased or acquired DexCom common stock during the Class Period, spanning January 8, 2024, to July 25, 2024.
2. Financial Losses: The investor must have suffered financial losses as a direct result of the alleged securities fraud perpetrated by DexCom and its executives.
3. Typicality and Adequacy: The investor's legal claims must be typical of those asserted on behalf of the class, and they must demonstrate their ability to adequately represent the interests of the entire class through experience, resources, and the absence of conflicts of interest.

It is crucial to note that both domestic and international investors who meet these criteria are eligible to seek appointment as the lead plaintiff in the DexCom class action lawsuit, as courts have consistently recognized the rights of non-U.S. investors in securities class actions.

LEGAL REQUIREMENTS FOR PREVAILING IN THE DexCom CLASS ACTION LAWSUIT

1. Material Misrepresentation or Omission
2. Scienter
3. Connection to Securities Transaction
4. Reliance
5. Economic Loss
6. Loss Causation

STAGES OF THE DexCom CLASS ACTION LAWSUIT

1. ​Consolidation and Lead Plaintiff Appointment
2. Filing of Consolidated Complaint
3. Motion to Dismiss
4. Class Certification
5. Discovery
6. Settlement Negotiations and Mediation
7. Summary Judgment Motions
8. Trial
9. Appeals

CONTINGENCY FEE ARRANGEMENTS AND COST CONSIDERATIONS

Give DexCom stock loss lawyer Timothy L. Miles a call about the Dexcom class action lawsuit

Many securities' litigation attorneys, including Timothy L. Miles, operate on a contingency fee basis, which means:

• Clients do not pay any upfront fees or costs.
• Instead, the attorney's fees and expenses are deducted from any settlement or judgment recovered on behalf of the class, typically as a court-approved percentage of the total recovery.

​
This arrangement ensures that investors can pursue their legal rights without bearing the financial burden of costly litigation, as the attorneys assume the risk and only receive compensation if they achieve a successful outcome for the class.

---

FREQUENTLY ASKED QUESTIONS ABOUT THE DexCom CLASS ACTION LAWSUIT

Can I serve as a lead plaintiff in the class action against DexCom if I purchases shares outside of the class period?

​No.  Even if you suffered losses in DexCom ​​​stock, if you purchased securities outside of the Class period, you will not be able to participate in the DexCom class action lawsuit.

Can I serve as a lead plaintiff in the class action against DexCom if I am serving as lead plaintiff in another securities fraud case?

​​​​Yes, unless you have been a lead plaintiff in more than five securities class actions during any three-year period which is expressly prohibited by the securities laws. Otherwise, if you suffered losses in DexCom stock, you may move to be appointed lead plaintiff in the DexCom lawsuit.

Can the court appoint more than one lead plaintiff in the DexCom class action lawsuit?

​​​Yes, at its discretion the Court may appoint a person, entity, or group of persons and/or entities as Lead Plaintiffs in the DexCom class action lawsuit.

How do I know if I am a member of the class in the class action against DexCom?

​​​If you purchased shares during the class period and suffered losses in DexCom stock, then you are most likely a member of the class in the DexCom lawsuit and may participate in the DexCom ​lawsuit since you suffered losses in DexCom class action lawsuit.

Resources for Investors in the DEXCOM Class Action Lawsuit and Others

• Seeking Alpha
• A Wealth of Common Sense
• Better Investing
• U. S. Securities & Exchange Commission
• Investor.gov
• Yahoo Finance
• Investopedia

CONTACT DexCom STOCK LOSS LAWYER TODAY TIMOTHY L MILES TODAY ABOUT A DexCom CLASS ACTION LAWSUIT

​If you suffered losses in DexCom ​stock, contact DexCom stock loss lawyer Timothy L. Miles today for a free case evaluation about a DexCom class action lawsuit. Call today and see what a DexCom stock loss lawyer could do for you if you suffered losses in DexCom  stock. ​This will most likely be the only call you need to make. (855) 846–6529 or [email protected]. ​

DEXCOM CLASS ACTION LAWSUIT
DEXCOM STOCK LOSS LAWYER
TIMOTHY L. MILES
300 CENTERVIEW DR, UNIT 247
BRENTWOOD, TN 27027
​855-846-6528

FREE CASE EVALUATION: CLASS ACTION AGAINST DEXCOM
If you suffered losses in DexCom stock, call DexCom stock loss lawyer Timothy L. Miles today for a
free case evaluation about a DexCom ​class action lawsuit. 
​855-846-6528​